BEFORE ORDERING THE PRODUCT, PLEASE MAKE SURE THAT THIS PRODUCT IS LEGAL TO IMPORT TO YOUR DESTINATION COUNTRY (PLEASE CHECK MHRA WEBSITE TO SEE IF THE PRODUCT IS NOT PROHIBITED IN UK). NOT AVAILABLE FOR SALE TO UK CONSUMERS.
PLEASE CONTACT US THROUGH EMAIL SALES@RAWPODERS.CO.UK IF YOU WISH TO ORDER LARGE QUANTITIES
What is Phenibut? Phenibut is one of the most popular nootropic supplements on the market today – a substance that may positively influence cognitive brain function, sleep and mood. It is mostly know for its benefits while treating insomnia, general anxiety disorder and reducing stress.
Phenibut may help to reduce stress and anxiety Users, who tried this nootropic, claimed that the most intensive effect they experienced was the feeling of complete relaxation. Most importantly, the calming effect of this substance does not affect ability to concentrate and does not leave a foggy feeling.
Phenibut may enhance mood Phenibut is a derivative of gamma aminobutyric acid (GABA), which is a primary neurotransmitter that operates in central nervous system. Phenibut has as similar molecular structure to GABA but crosses the blood-brain barrier more effectively. This nootropic has anti-depressant properties and can reduce irritability.
Phenibut may help to get better sleep If you have trouble falling asleep at night or want to wake up more rested, Phenibut is the right choice for you. It has a strong calming effect and increases the ability to relax.
Helps to improve cognitive brain function
Helps to decrease stress
Helps to improve mood
Helps to improve sleep and recovery
Purity check board
The optimal daily dosage of Phenibut is 250-1000 mg. We recommend trying out small dosages at first and do not exceed the recommended dosage. Phenibut has quite a long half life which means that you should take it and wait for a few hours for the effect to appear. Scoop included!
Not recomended with
Pure Phenibut (B-Phenyl-Y-aminobutyric acid).
Lapin, I. (2001). "Phenibut (beta-phenyl-GABA): A tranquilizer and nootropic drug" (pdf). CNS Drug Reviews 7 (4): 471–481